AbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong …

In This Article: ABBV. Total Net Revenues: Nearly $14.5 billion, reflecting 4.9% operational growth. Ex-Humira Growth Platform: Reported growth of nearly 18%. Adjusted Earnings Per …

CouponFollow Extension

9%
OFF

AbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong …

1 week from now

In This Article: ABBV. Total Net Revenues: Nearly $14.5 billion, reflecting 4.9% operational growth. Ex-Humira Growth Platform: Reported growth of nearly 18%. Adjusted Earnings Per …

yahoo.com

$10.67
OFF

AbbVie Reports Third-Quarter 2024 Financial Results | AbbVie

1 week from now

Oct 30, 2024 · AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.67 - $10.87 to $10.90 - $10.94, which includes an unfavorable impact of $0.64 per share …

abbvie.com

$0.15
OFF

AbbVie (ABBV) Q3 2024 Earnings Call Transcript - The Globe And …

1 week from now

Oct 30, 2024 · We are also raising our full-year adjusted earnings per share guidance by $0.15 and now expect adjusted EPS between $10.90 and $10.94. In addition to achieving strong …

theglobeandmail.com

$3
OFF

AbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Call Transcript - MSN

1 week from now

AbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations were $2.92. Operator: Good …

msn.com

$14.46
OFF

AbbVie Inc (ABBV) Q3 2024 Earnings: Revenue Beats At $14.46B, GA

1 week from now

On October 30, 2024, AbbVie Inc (ABBV, Financial) released its 8-K filing detailing the financial results for the third quarter of 2024. The pharmaceutical company, known for its strong …

gurufocus.com

74%
OFF

AbbVie (ABBV) Surpasses Q3 Earnings And Revenue Estimates

1 week from now

Oct 30, 2024 · AbbVie (ABBV) delivered earnings and revenue surprises of 2.74% and 1.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies …

zacks.com

$14.46
OFF

Transcript : AbbVie Inc., Q3 2024 Earnings Call, Oct 30, 2024

1 week from now

Oct 30, 2024 · AbbVie's Q3 Earnings, Revenue Rise; Fiscal 2024 Adjusted EPS Guidance Lifted 08:03am: MT Earnings Flash (ABBV) ABBVIE Posts Q3 Revenue $14.46B 07:54am: MT …

marketscreener.com

$14.46
OFF

Transcript : AbbVie Inc., Q3 2024 Earnings Call, Oct 30, 2024

1 week from now

Oct 30, 2024 · AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq ... Earnings Flash (ABBV) ABBVIE Posts Q3 Revenue $14.46B 11:54am: MT Earnings Flash …

marketscreener.com

$845
OFF

AbbVie (ABBV) Q3 2024 Earnings Call Transcript - MSN

1 week from now

Story by Motley Fool Transcribing. • 10h. AbbVie(NYSE: ABBV) Q3 2024 Earnings Call. Oct 30, 2024, 9:00 a.m. ET. Read More: Earn up to $845 cash back this year just by changing how …

msn.com

74%
OFF

AbbVie (ABBV) Earnings Date And Reports 2024 - MarketBeat

1 week from now

3 days ago · AbbVie (ABBV) Earnings Date, Estimates & Call Transcripts $164.99-4.64 (-2.74%) (As of 11/15/2024 ET) Add. Compare ... AbbVie issued Q3 2024 earnings on October 30, …

marketbeat.com

$12
OFF

LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript

1 week from now

Total operating expenses for Q3 2024 were approximately $12.9 million compared to $19.9 million for the same period in 2023. Our Q3 2024 cash burn, net of interest income was approximately …

seekingalpha.com

FAQs about AbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong … Coupon?

Does AbbVie Inc (ABV) beat earnings expectations?

AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations were $2.92. Operator: Good morning, and thank you for standing by. Welcome to the AbbVie Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only until the question-and-answer portion of this call. ...

Is AbbVie Inc (abbv) a good stock to buy?

AbbVie Inc (ABBV) reports robust sales growth driven by Skyrizi and Rinvoq, raises full-year guidance, and announces a 5.8% dividend increase. ...

Does AbbVie provide information about risks and uncertainties?

Additional information about these risks and uncertainties is included in our SEC filings. AbbVie undertakes no obligation to update these forward-looking statements, except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand AbbVie's business performance. ...

Is AbbVie performing well?

AbbVie is performing exceptionally well, and I’m extremely pleased with the execution against our strategic priorities, including continued double-digit sales growth from our ex-Humira platform, the closing and integration of Cerevel Therapeutics and the progress we are making to build and advance a compelling pipeline of innovative medicines. ...

How did AbbVie's diversified portfolio perform?

Turning to our results, AbbVie’s diversified portfolio delivered sales that were $260 million above our expectations and reflect robust mid-single-digit operational sales growth. Our ex-Humira platform drove this over achievement, including growth of nearly 18%. ...

Who is the CEO of AbbVie?

Robert Michael; Chief Executive Officer; AbbVie Inc Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Carrie Strom; Senior Vice President, AbbVie and President, Global Allergan Aesthetics; AbbVie Inc Roopal Thakkar; Executive Vice President, Research & Development and Chief Scientific Officer; AbbVie Inc ...